Buzz: A buyer is in talks to acquire a big stake in Celltrion

The buzz about the potential sale of a big stake in Celltrion, Korea's biosimilars developer, picked up after the company filed a statement with regulators indicating that discussions with a potential buyer or buyers are underway. Celltrion recently won an approval in Europe for its copycat version of Remicade. The company president retained JP Morgan last year to help market his stake in the company. Story

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.